

March 8, 2023

Mark Iwicki  
Chief Executive Officer  
Kala Pharmaceuticals, Inc.  
1167 Massachusetts Avenue  
Arlington, MA 02476

Pharmaceuticals, Inc.

Statement on Form S-3

Re: Kala

Registration

Filed March 3, 2023

File No. 333-270266

Dear Mark Iwicki:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Crawford at 202-551-7767 with any questions.

Please contact Daniel

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Scott Lunin, Esq.